ES2038747T3 - Compuestos antineoplasicos. - Google Patents

Compuestos antineoplasicos.

Info

Publication number
ES2038747T3
ES2038747T3 ES198888300064T ES88300064T ES2038747T3 ES 2038747 T3 ES2038747 T3 ES 2038747T3 ES 198888300064 T ES198888300064 T ES 198888300064T ES 88300064 T ES88300064 T ES 88300064T ES 2038747 T3 ES2038747 T3 ES 2038747T3
Authority
ES
Spain
Prior art keywords
compounds
och3
substances
antineoplasic
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198888300064T
Other languages
English (en)
Inventor
George R. Pettit
Sheo Bux Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona Board of Regents of ASU
Original Assignee
Arizona Board of Regents of ASU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona Board of Regents of ASU filed Critical Arizona Board of Regents of ASU
Application granted granted Critical
Publication of ES2038747T3 publication Critical patent/ES2038747T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE HAN AISLADO NUEVOS COMPUESTOS ANTINEOPLASTICOS, ESTRUCTURALMENTE DILUCIDADOS Y SINTETIZADOS, QUE TIENEN LA FORMULA ESTRUCTURAL (I) O (II), DONDE R1 ES OH U OCH3; R2 ES H U OCH3; O R1R2 ES -OCH2O-, R3 ES H U OH; Y R4 ES OH U OCH3, Y DONDE LA CONFIGURACION DEL DOBLE ENLACE EN LOS COMPUESTOS DE FORMULA (I) ES CIS. ESTAS SUSTANCIAS SE HAN DENOMINADO A-1, A-2, A-3, B-1, B-2, B-3 Y B-4 COMBRETASTAINA. SE DESCRIBEN PREPARACIONES FARMACEUTICAS QUE CONTIENEN LAS SUSTANCIAS Y METODOS PARA TRATAR UN HUESPED CON UN TUMOR NEOPLASTICO CON LA PREPARACION.
ES198888300064T 1987-01-06 1988-01-06 Compuestos antineoplasicos. Expired - Lifetime ES2038747T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59087A 1987-01-06 1987-01-06

Publications (1)

Publication Number Publication Date
ES2038747T3 true ES2038747T3 (es) 1993-08-01

Family

ID=21692158

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198888300064T Expired - Lifetime ES2038747T3 (es) 1987-01-06 1988-01-06 Compuestos antineoplasicos.

Country Status (8)

Country Link
US (2) US5409953A (es)
EP (1) EP0276051B1 (es)
JP (1) JP2558131B2 (es)
AT (1) ATE66452T1 (es)
CA (1) CA1338645C (es)
DE (1) DE3864269D1 (es)
ES (1) ES2038747T3 (es)
GR (1) GR3003111T3 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
CA1338645C (en) * 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
DE68907095T2 (de) * 1988-03-21 1994-01-05 Boehringer Ingelheim Pharma Verbindungen zur Verhinderung der Biosynthese von der Lipoxygenase abgeleiteten Metaboliten der Arachidonsäure.
GB9106177D0 (en) * 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
US5430062A (en) * 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
IT1256354B (it) * 1992-08-31 1995-12-01 Francesca Pelizzoni Derivati della combretastatina ad attivita' anti-tumorale e procedimento per la loro preparazione
FR2728570B1 (fr) * 1994-12-23 1997-04-11 Synthelabo Derives de 1-oxo-2-(phenylsulfonylamino)pentylpiperidine, leur preparation et leur application en therapeutique
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
EP1068870B1 (en) 1998-04-03 2006-06-07 Ajinomoto Co., Inc. Antitumor agents
US6245814B1 (en) 1998-05-08 2001-06-12 Calyx Therapeutics, Inc. Diphenylethylene compounds
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
US6448450B1 (en) * 1998-05-08 2002-09-10 Calyx Therapeutics, Inc. 1-(3,5-dimethoxyphenyl)-2-(4-hydroxyphenyl)-ethylene for diabetes treatment
US6624197B1 (en) 1998-05-08 2003-09-23 Calyx Therapeutics, Inc. Diphenylethylene compounds
CA2358925C (en) * 1999-02-18 2010-04-20 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
EP1832290A3 (en) * 1999-02-18 2010-11-17 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US6525093B1 (en) 1999-11-08 2003-02-25 Calyx Therapeutics Inc. Compounds to treat diabetes and associated conditions
US20080108825A1 (en) * 1999-11-08 2008-05-08 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US20020002200A1 (en) * 2000-02-04 2002-01-03 Bishwagit Nag Novel diphenylethylene compounds
US20080103302A1 (en) * 2000-02-04 2008-05-01 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
ATE368046T1 (de) * 2000-03-10 2007-08-15 Univ Baylor Tubulin bindende liganden
PT1278758E (pt) * 2000-04-27 2011-12-22 Univ Arizona Pró-fármacos de fosfato de combretastatina a-1 e fosfato de combretastatina b-1
US6743937B2 (en) 2000-07-17 2004-06-01 Oxigene, Inc. Efficient method of synthesizing combretastatin A-4 prodrugs
AU2002216228A1 (en) * 2000-12-21 2002-07-01 Cancer Research Ventures Limited Substituted stilbenes, their reactions and anticancer activity
GB0031263D0 (en) * 2000-12-21 2001-01-31 Paterson Inst For Cancer Res Materials and methods for synthesizing stilbenes
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
CA2432792C (en) 2000-12-22 2012-04-03 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
WO2002058535A2 (en) 2000-12-26 2002-08-01 Oxigene, Inc. Use of combretastatin a4 and its prodrugs as an immune enhancing therapy
WO2002102766A2 (en) 2001-06-15 2002-12-27 Arizona Board Of Regents Combretastatin a-3 prodrug
CN1527704B (zh) * 2001-07-13 2011-05-18 奥克斯吉尼有限公司 治疗眼病的组合物和微管蛋白结合剂用法
US20030129193A1 (en) * 2001-09-27 2003-07-10 Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. Combined methods for tumor vasculature coaguligand treatment
JP2005514450A (ja) * 2001-12-21 2005-05-19 アリゾナ ボード オブ リーゼンツ コンブレタスタチンａ−２プロドラッグの合成
EP2281578A3 (en) 2002-07-15 2011-04-13 Board of Regents, The University of Texas System Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer
US20060100179A1 (en) * 2002-08-14 2006-05-11 Pero Ronald W Compositions and methods for use in targeting vascular destruction
WO2004078126A2 (en) * 2003-02-28 2004-09-16 Oxigene, Inc. Compositions and methods with enhanced therapeutic activity
GB0306908D0 (en) * 2003-03-26 2003-04-30 Angiogene Pharm Ltd Bioreductively activated stilbene prodrugs
AU2006214164B2 (en) * 2005-02-17 2010-12-09 Synta Pharmaceuticals Corp. Isoxazole combretastin derivatives for the treatment of disorders
CN1907989B (zh) * 2005-08-02 2011-08-17 浙江天皇药业有限公司 毛兰素盐及其制备方法和包含其的药物组合物
EP1976505A1 (en) * 2005-11-14 2008-10-08 Abraxis BioScience, Inc. Combretastatin derivatives and related therapeutic methods
US20070276172A1 (en) 2006-03-28 2007-11-29 Sinha Arun K Single step microwave induced process for the preparation of substituted stilbenes and its analogs
US20090011060A1 (en) * 2007-07-06 2009-01-08 Peter Koepke Campsiandra angustifolia extract and methods of extracting and using such extract
US20090017140A1 (en) * 2007-07-09 2009-01-15 Peter Koepke Maytenus abenfolia extract and methods of extracting and using such extract
US20090035395A1 (en) * 2007-08-01 2009-02-05 Peter Koepke Spondias mombin l. extract and methods of extracting and using such extract
US7879369B2 (en) * 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
EA034136B1 (ru) 2007-11-09 2020-01-09 Перигрин Фармасьютикалз, Инк. Изолированное антитело, которое связывается с vegf, и его применения
JP5302328B2 (ja) 2007-11-21 2013-10-02 オキシジーン， インコーポレイテッド 造血性新生物を治療するための方法
CN101723813A (zh) * 2008-10-15 2010-06-09 上海华理生物医药有限公司 一种乙氧基二苯乙烷衍生物及其制备方法和用途
US8716532B2 (en) 2009-03-27 2014-05-06 Council Of Scientific And Industrial Research One pot multicomponent synthesis of some novel hydroxy stilbene derivatives with alpha, beta-carbonyl conjugation under microwave irradiation
JP2014527036A (ja) 2011-06-27 2014-10-09 ザ ジャクソン ラボラトリー 癌および自己免疫疾患の処置のための方法および組成物
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
JP6175399B2 (ja) * 2014-03-31 2017-08-02 静岡県公立大学法人 スチルベン類縁化合物を有効成分とする抗炎症剤
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
WO2016130969A1 (en) 2015-02-13 2016-08-18 George Robert Pettit Silstatin compounds
EP3337495A4 (en) 2015-08-18 2019-04-10 Mateon Therapeutics, Inc. USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019094709A1 (en) 2017-11-09 2019-05-16 Pettit George R Betulastatin compounds
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
CN113577020B (zh) * 2021-08-16 2022-09-23 海南鑫开源医药科技有限公司 一种玻璃体腔内注射剂、其制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA463336A (en) * 1950-02-21 Eli Lilly And Company Method of producing dialkoxy stilbenes
US2496968A (en) * 1945-10-05 1950-02-07 Burroughs Wellcome Co Alpha:beta:2:2'-tetramethyl-4:4'-dihydroxystilbene
US3198840A (en) * 1960-05-11 1965-08-03 Armour Pharma Derivatives of diphenyl synthetic estrogens
US3293307A (en) * 1963-12-23 1966-12-20 Sun Oil Co Preparation of substituted ethanes
GB1046380A (en) * 1964-07-06 1966-10-26 American Cyanamid Co New hypocholesteremic compositions
US3577230A (en) * 1968-10-18 1971-05-04 Arizona Chem Process of applying novel algicides
US3968234A (en) * 1975-03-05 1976-07-06 The United States Of America As Represented By The Secretary Of Agriculture Cinnamyl-sesamol derivatives as insect chemosterilants
DE2658307C2 (de) * 1976-12-22 1979-03-15 Klinge Pharma Gmbh & Co, 8000 Muenchen Di-O'-hydroxyphenyD-alkanverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US4326055A (en) * 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
US4482728A (en) * 1981-11-05 1984-11-13 The United States Of America As Represented By The Secretary Of Agriculture Polybutylbenzylphenols and benzyl-3,4-methylenedioxbenzenes in insect population control
CA1338645C (en) * 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
DE3866371D1 (de) * 1987-02-13 1992-01-09 Ciba Geigy Ag Diphenylaethylen-derivate.
GB9106177D0 (en) * 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof

Also Published As

Publication number Publication date
US5569786A (en) 1996-10-29
DE3864269D1 (de) 1991-09-26
EP0276051B1 (en) 1991-08-21
EP0276051A2 (en) 1988-07-27
US5409953A (en) 1995-04-25
GR3003111T3 (en) 1993-02-17
JPS63233939A (ja) 1988-09-29
JP2558131B2 (ja) 1996-11-27
EP0276051A3 (en) 1988-11-30
ATE66452T1 (de) 1991-09-15
CA1338645C (en) 1996-10-15

Similar Documents

Publication Publication Date Title
ES2038747T3 (es) Compuestos antineoplasicos.
AU599792B2 (en) Anti-parkinsonian indolone derivatives
HU206701B (en) Process for producing substituted flavonoid derivatives and salts and pharmaceutical compositions containing these compounds
AU669122B2 (en) New pyrazine derivatives, their preparation and their use
AU611113B2 (en) Basically substituted phenylacetonitriles, their preparation and drugs containing these compounds
DE3477488D1 (en) Polymethoxybenzyl piperazine derivatives, processes for their preparation and pharmaceutical compositions containing said derivatives
EP0331092A3 (en) Alpha-amino-carboxylic-acid derivatives, their preparation and use
FI864970A0 (fi) Nya kristallina salter av aryloxi-propanolaminer, foerfarande foer deras framstaellning och deras anvaendning.
ES2016305B3 (es) Compuestos de piperazina, procedimiento para prepararlos y composicion farmaceutica y su uso.
PT86282A (en) Novel anthracyclinederivates a process for preparing and pharmaceutical compounds containing them
IL76345A (en) Proline derivatives and antihypertensive and anti-glaucoma pharmaceutical preparations containing the same
CA2038025A1 (en) Optically active alkylenedioxybenzene derivatives and their use in therapy
ZA874470B (en) New tetrahydrobenzothiazoles,and the preparation and use thereof
FR2601021B2 (fr) Fraction immunogene active a l'egard des bilharzioses, sa preparation, compositions immunisantes la contenant
FI853868A0 (fi) Pyridinderivat, foerfarande foer framstaellning av dessa och farmaceutiska foereningar innehaollande dessa.
WO1987003590A1 (en) Medicament for the treatment of diseases of the liver
EP0449011A3 (en) Stereoselective process for the preparation of 2-amino-ethanol derivatives having a central analgesic activity and intermediates thereof
JPS6483069A (en) Phenanthridine derivatives, manufacture and composition
BG95629A (en) Derivatives of 10, 11, 12, 13 - tetrahytdrodesmicozine, method for preparing them, and their use as pharmaceutical preparations
DE69011174T2 (de) Catecholaminester.
FR2592653A1 (fr) Derives de chromene, procede d'obtention et compositions pharmaceutiques.
AU7250987A (en) Pharmaceutical compositions for use in improving oxygenation of the brain and a process for their production

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 276051

Country of ref document: ES